Atrium Therapeutics, Inc. (RNA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 7 | 9 | 9 | 10 | 11 | 19 | 23 | 34 |
| Operating profit | $m | -77 | -96 | ||||||
| Net profit | $m | -44 | -118 | -174 | -212 | -322 | -77 | -93 | -78 |
| EPS reported | $ | -4.48 | -3.85 | ||||||
| Operating cashflow per share | $ | -2.40 | -2.95 | ||||||
| Capex per share | $ | 0.08 | 0.17 | ||||||
| FCF per share | $ | -2.49 | -3.12 | ||||||
| Free cash flow | $m | -43 | -57 | ||||||
| Net debt | $m | -270 | -263 | ||||||
| Book value equity | $m | 207 | 215 | ||||||
| Book value per share | $ | 12.11 | 12.54 | ||||||
| Number of shares | m | 17.11 | 17.11 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.22 | 1.18 | ||||||
| P/S LTM | x | 13.56 | 10.74 | ||||||
| P/FCF LTM | x | -5.93 | -4.40 | ||||||
| EV/EBITDA LTM | x | 0.18 | 0.15 | ||||||
| EV/Sales LTM | x | -0.75 | -2.22 | ||||||
| Earnings Yield LTM | % | -30.38% | -29.46% | ||||||
| FCF Yield | % | -16.87% | -22.71% | ||||||
| Quality | |||||||||
| ROE | % | -36.99% | -29.67% | ||||||
| ROIC | % | -31.92% | -23.91% | ||||||
| Operating margin | % | -4.13% | -3.19% | ||||||
| Gross margin | % | +100.00% | +99.26% | ||||||
| FCF/Sales | % | -228.67% | -260.43% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +70.85% | +115.64% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -11.59 | -34.07 | ||||||
| Net Debt/EBITDA | x | 3.48 | 4.12 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +1.22% | ||||||
| Net debt/Equity | x | -1.30 | -1.22 | ||||||
| Gross debt/equity | x | 0.02 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free